Authors
Latest:
Irene Agodoa, MD, on Addressing GVHD Risks in Treating Hematologic MalignanciesThe senior vice president and head of medical affairs at Orca Bio discussed how Orca-T has been developed to lower the risk of graft-versus-host disease.
Latest:
Addressing Unmet Needs in Mantle Cell Lymphoma With CAR T Therapy: Anita Kumar, MDThe medical oncologist from Memorial Sloan Kettering Cancer Center discussed efforts made to address areas of unmet need in mantle cell lymphoma.
Latest:
Achieving Remission in Chronic Lymphocytic Leukemia With CD4+ CAR T-Cells: Jan Joseph Melenhorst, PhDThe translational immunologist and research professor at Perelman School of Medicine, University of Pennsylvania, discussed persistence of CD4+ CAR T-cells in CLL.
Latest:
Treating Endothelial Disease With One Cornea DonorEdward Holland, MD, chief medical advisor, discussed an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Latest:
Improving Safety With CAR Engager ProteinsPaul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s research on CAR T therapies.
Latest:
Gene Therapy for Retinal and Neurological DiseasesMagali Taiel, MD, chief medical officer, GenSight Biologics, discussed future research the company plans to pursue.
Latest:
David S. Hong, MD, on the SURPASS Clinical Trial and TCR T-cell Therapy in Solid TumorsHong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.
Latest:
Swati Naik, MBBS, on Investigating CD123-CAR T Therapy for Relapsed AMLThe assistant member at St. Jude Children’s Research Hospital discussed updated data from a phase 1 study being conducted at the hospital.
Latest:
Jeffrey Miller, MD, on Emerging Research With Natural Killer CellsThe deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.
Latest:
Milind Desai, MD, MBA, on Clinically Evaluating MYBPC3–Associated Hypertrophic Cardiomyopathy Gene TherapyThe director of the Center for Hypertrophic Cardiomyopathy at the Cleveland Clinic discussed the design of the MyPeak-1 clinical trial for TN-201 and the associated MyCLIMB natural history study.
Latest:
Zinaida Good, PhD, on Exploring CAR-T Expansion Through Lineage TracingThe instructor at Stanford Institutes of Medicine discussed the key takeaways of her research into the factors that affect CAR-T expansion.
Latest:
Shannon L. Maude, MD, PhD, on Favorable Safety of Tisagenlecleucel in Pediatric B-ALLThe oncologist from Children's Hospital of Philadelphia discussed long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
Latest:
Richard Fessler, MD, on OPC1 Improving Quality of Life With Spinal Cord InjuryThe professor of neurosurgery at Rush University Medical School discussed follow-up in the phase 1/2 trial of LCTOPC1 and further research to be done.
Latest:
Piers Blombery, MBBS, PhD, on More ctDNA, MRD Biomarker Use in Blood Cancer for 2024The associate professor at Peter MacCallum Cancer Centre discussed highlights from the 2023 ASH meeting.
Latest:
Applying a Novel Gene Editing Approach to Chronic Hepatitis BPrecision Bio is taking a novel approach to gene editing to deploy a cure for patients with chronic hepatitis B.
Latest:
Leticia Tordesillas, PhD, on the Potential of γδ CAR T-cells to Treat Bone Metastatic Prostate CancerThe research scientist at Moffitt Cancer Center discussed the results of the preclinical study she presented at the 2023 AACR annual meeting and avenues for further research.
Latest:
Future Research With Stem Cell Therapies in Hematologic MalignanciesThe chief executive and chief medical officers of Vor Biopharma discussed the company’s future research and plans.
Latest:
Alexandra Lisi on Scaling Manufacturing Efficiency to Support Cell TherapyThe cell therapy field applications staff scientist at ThermoFisher discussed advantages of the company’s DynaCellect system.
Latest:
Surbhi Sidana, MD, on Assessing Ide-cel in Patients With R/R Multiple Myeloma and Renal ImpairmentThe assistant professor of medicine, bone marrow transplantation and cellular therapy, Stanford, discussed favorable data from a real-world experience study.
Latest:
IND for Gene Replacement Therapy for Inherited Retinal Dystrophy Cleared by FDAThe company is developing a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of patients with RPE65 mutation-associated retinopathies.
Latest:
Later-Generation Cell Therapies Increase Utility in Hematologic MalignanciesCAR T-cell therapy use will likely expand to a wider array of hematologic malignancies.
Latest:
Jay Spiegel, MD, FRCPC, on 5-Year Real-World Outcomes From Axi-cel in R/R LBCLThe hematologist and cell therapist from the University of Miami Sylvester Comprehensive Cancer Center spoke about long-term outcome data he presented at ASH’s 2023 conference.
Latest:
Veit Bücklein, Dr Med, on Research Trends in Hematological Malignancy Cell TherapyThe postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed research he was excited to see at ASH 2023 and in the field in general.
Latest:
Samir Parekh, MD, on Surprising Efficacy of Sequential T-Cell Redirection Therapy in Multiple MyelomaThe director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.
Latest:
Jay Barth, MD, on Ascidian Therapeutics' Developments in Gene TherapyCGTLive's sister publication spoke with Barth, the chief medical officer at Ascidian, about the company’s attempts to develop a new method of administration for gene therapy at ARVO 2023.
Latest:
Omer A. Abdul Hamid, MD, on Sharing Expertise With Gene Therapy LogisticsThe pediatric neurologist at Nemours Children’s Health offered advice and discussed his experiences delivering pediatric gene therapy.
Latest:
Sung-Yun Pai, MD, on Further Research With Lentiviral Gene Therapy for X-SCIDThe senior investigator at the National Cancer Institute Center for Cancer Research discussed unmet needs that remain and further research to be done.
Latest:
Evan Mizerak, on Developing an ASO Targeting CAPN2 for ALSThe lead of preclinical research at Amylyx Pharmaceuticals discussed the literature supporting AMX0114’s target and its upcoming trial design.
Latest:
Allogeneic Stem Cell Transplant for Acute Myeloid LeukemiaThe hematologist from UC Health discussed the role of allogeneic stem cell transplant at first remission based on risk stratification.
Latest:
Alba Gonzalez-Junca, PhD, on Logic-gated CAR-NK Cell DevelopmentThe associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.
